GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
AbbVie expands bispecific cancer med push with up to $2.5 billion deal with Germany's Disco - Finance news and analysis from Global Banking & Finance Review
Finance

AbbVie expands bispecific cancer med push with up to $2.5 billion deal with Germany's Disco

Published by Global Banking & Finance Review

Posted on November 19, 2026

2 min read

· Last updated: November 19, 2026

Add as preferred source on Google

AbbVie Inks $2.5 Billion Deal with Disco Pharmaceuticals for Bispecific Cancer Therapies

AbbVie and Disco Pharmaceuticals Collaborate on Next-Generation Cancer Treatments

By Bhanvi Satija and Siddhi Mahatole

Deal Overview and Financial Terms

Nov 19 (Reuters) - AbbVie agreed to pay up to $2.54 billion to develop cancer treatments with Disco Pharmaceuticals, the Germany-based private biotech said on Thursday, marking an early-stage push by the drugmaker on next-generation bispecific therapies.

Understanding Bispecific Antibodies

Bispecific antibodies, a class of cancer medicines that bind two targets at once, have drawn increased interest from big drugmakers including Bristol Myers Squibb, Pfizer and Merck.

Previous AbbVie Investments

In January, AbbVie paid RemeGen $650 million upfront for rights outside China to a bispecific medicine targeting solid tumors.

Deal Structure and Therapeutic Focus

Disco will receive $40 million upfront and up to $2.5 billion in milestone payments as part of the deal to develop so-called AND-gated bispecific therapeutics for solid tumors. It will also be eligible for tiered royalties on worldwide net sales.

Innovative Approach to Cancer Cell Targeting

The approach is designed to recognize cancer cells only when two target proteins are present simultaneously, potentially reducing damage to healthy tissue.

Roles and Responsibilities

Disco CEO Mark Manfredi said his company will be responsible for the research and discovery. AbbVie will have the right to exclusively license selected programs for further development.

Collaboration Insights

"(AbbVie) brings a wealth of information, a wealth of experience in target biology, so we will learn from them and we will work with them on how to select targets," said Manfredi.

Development Timeline and Industry Context

The deal is at a very early stage. Disco did not disclose how many programs could be covered or when any could enter clinical development, and AbbVie's license option applies only after Disco completes specified research.

Pipeline and Future Plans

Disco has been developing AND-gated therapies for small-cell lung and colorectal cancer, and Manfredi said the company will select a development candidate in the second half of next year.

Other Major Bispecific Deals

Other recent bispecific deals include Bristol Myers Squibb's up to $11.1 billion partnership with BioNTech, Takeda's multibillion-dollar deal with China's Innovent and UCB's $2.2 billion acquisition of Candid Therapeutics.

(Reporting by Siddhi Mahatole in Bengaluru and Bhanvi Satija in London; Editing by Sahal Muhammed)

References

Frequently Asked Questions

What is the value of AbbVie's deal with Disco Pharmaceuticals?
AbbVie agreed to pay up to $2.54 billion, including a $40 million upfront payment and potential milestone payments.
What are bispecific antibodies used for in this deal?
They are next-generation cancer medicines targeting two proteins to help treat solid tumors more effectively.
What role does Disco Pharmaceuticals play in the partnership?
Disco will handle research and discovery, with AbbVie eligible to license programs after research milestones.
What is the purpose of AND-gated bispecific therapeutics?
They aim to recognize cancer cells only when two target proteins are present, reducing harm to healthy tissue.
Are there any similar recent bispecific deals in the industry?
Yes, including Bristol Myers Squibb's $11.1B partnership with BioNTech and UCB's $2.2B acquisition of Candid Therapeutics.

Tags

Related Articles

More from Finance

Explore more articles in the Finance category